178 related articles for article (PubMed ID: 37270700)
1. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.
Sun L; Bleiberg B; Hwang WT; Marmarelis ME; Langer CJ; Singh A; Cohen RB; Mamtani R; Aggarwal C
JAMA Oncol; 2023 Aug; 9(8):1075-1082. PubMed ID: 37270700
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
5. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
6. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
8. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
9. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
[TBL] [Abstract][Full Text] [Related]
10. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.
Tiu AC; Potdar R; Djibo DA; Masab M; Dourado C
Med Oncol; 2018 Jun; 35(7):109. PubMed ID: 29915891
[TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Haratani K; Hayashi H; Chiba Y; Kudo K; Yonesaka K; Kato R; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Nakagawa K
JAMA Oncol; 2018 Mar; 4(3):374-378. PubMed ID: 28975219
[TBL] [Abstract][Full Text] [Related]
14. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
15. Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
Parikh RB; Min EJ; Wileyto EP; Riaz F; Gross CP; Cohen RB; Hubbard RA; Long Q; Mamtani R
JAMA Oncol; 2021 Dec; 7(12):1843-1850. PubMed ID: 34734979
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
Ricciuti B; Genova C; Bassanelli M; De Giglio A; Brambilla M; Metro G; Baglivo S; Dal Bello MG; Ceribelli A; Grossi F; Chiari R
Clin Lung Cancer; 2019 May; 20(3):178-185.e2. PubMed ID: 30910574
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
Stinchcombe TE; Miksad RA; Gossai A; Griffith SD; Torres AZ
Clin Lung Cancer; 2020 Sep; 21(5):389-394.e3. PubMed ID: 32409266
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment.
Huang X; Wu S; Chen S; Qiu M; Zhao Y; Wei J; He J; Zhao W; Tan L; Su C; Zhou S
Int Immunopharmacol; 2024 May; 132():111901. PubMed ID: 38554448
[TBL] [Abstract][Full Text] [Related]
20. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
